NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

PERSPECTIVES: The resurgence of Y2K skin-baring fashion trends coincides with the rise of prescription weight loss drugs like ...